Before diving into the highlights '24, we did put on the 20 years Molecular Partners logo because it is our 20 ... last year by the approval of Amgen's tarlatamab in [deltra] (ph), so we believe ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed last Friday at $324.86.

Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six months after a single repeat infusion, Opco points out. It believes extrapolating from Cartesian’s ...

THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner ...

THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The ...

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound. The pharma company ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...